藥明康德(02359.HK)預計中期經調整淨利潤增長約44.43%
格隆匯7月10日丨藥明康德(02359.HK)公告,公司預計2025年1月1日至2025年6月30日實現營業收入約人民幣 20,799.28 百萬元,同比增長約20.64%,其中持續經營業務收入同比增長約24.24%。
公司預計本期實現經調整非《國際財務報告準則》下歸屬於公司股東的淨利潤約人民幣6,314.80百萬元,同比增長約44.43%。
公司預計本期實現歸屬於公司股東的扣除非經常性損益的淨利潤約人民幣5,582.13百萬元,同比增長約26.47%,與經調整歸母淨利潤增速相比主要受到匯率波動的影響。
公司預計本期實現歸屬於公司股東的淨利潤約人民幣8,560.88百萬元,同比增長約101.92%,其中包含了出售聯營公司部分股權所獲得的投資收益;本期基本每股收益預計約人民幣3.01元╱股,同比增長約106.16%。
本期業績預增的主要原因:公司持續聚焦獨特的「一體化、端到端」CRDMO(合同研究、開發與生產)業務模式,緊抓客戶對賦能需求的確定性,不斷拓展新能力、建設新產能,持續優化生產工藝和提高經營效率,推動業務持續穩健增長,高效極致賦能客戶並致力於將更多新藥、好藥帶給全球病患。
本期非經常性損益項目對利潤的影響主要來自於出售持有的WuXiXDC Cayman Inc.部分股票的收益,本期預計收益約人民幣3,209.86百萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.